Tech Company Inital Public Offerings
AbCellera IPO
AbCellera was acquired by . AbCellera shares were listed on 12/10/2020.
Transaction Overview
Company Name
Announced On
12/10/2020
Transaction Type
IPO
Amount
$483,000,000
Proceeds Purpose
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to continue making investments in research and development efforts towards deepening our technology and expertise along our technology stack, to continue making investments in building our business development team and marketing our solutions to new and existing partners, as well as for general corporate purposes, including working capital, operating expenses and capital expenditures.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2215 Yukon St.
Vancouver BC, V5Y 0A1
Canada
Vancouver BC, V5Y 0A1
Canada
Phone
Website
Email Address
Overview
AbCellera Biologics (Nasdaq: ABCL) With the world's leading technology for screening and mapping of natural immune responses, we test antibodies from single B cells at depths of millions of cells per day. We unlock the power of natural immunity to discover the next generation of antibody therapies.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/10/2020: Battleface venture capital transaction
Next: 12/10/2020: Synctera venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs